top of page


Dr. Mark Larché holds the Canada Research Chair in Allergy & Immune Tolerance at McMaster University, Hamilton Ontario, Canada. He is a Professor in the Department of Medicine and also holds the McMaster University/GSK Chair in Lung Immunology at St. Joseph’s Healthcare, Hamilton. Dr. Larché’s research interests include the pathogenesis and treatment of chronic inflammation with a particular focus on allergic diseases, pathogenesis of autoimmune diseases (rheumatoid arthritis and scleroderma), immunological mechanisms of immunotherapy, and graft rejection. Over the past 20 years he has developed peptide immunotherapies based on the delivery of immunodominant T cell epitopes to induce immune tolerance.

Dr. Larché’s research program is funded by the Canadian Institutes of Health Research, Canada Research Chairs Program, Canada Foundation for Innovation, Ontario Research Fund, National Institutes of Health and the Scleroderma Society of Ontario.

Dr. Larché is a co-founder of Circassia Ltd. ( ), a biotechnology company developing vaccines for allergic diseases. More recently he was Founding Scientist of Adiga Life Sciences, a Joint Venture between Circassia Ltd and McMaster University.

bottom of page